Adrian Howd

Adrian G.
Howd is currently the Director at Viamet Pharmaceuticals, Inc., Independent Director at Viamet Pharmaceuticals Corp., Director & Principal at Brandon Point Industries Ltd., Director at Blueberry Therapeutics Ltd., and will be the Chief Financial & Business Officer at BiVictriX Therapeutics Plc starting in 2023.
Previously, he was the Chief Executive Officer at Malin Corp.
Plc from 2015 to 2018.
He also served as a Non-Executive Director at Kymab Ltd., Director at Poseida Therapeutics, Inc., Director at Wavebreak Therapeutics Ltd. from 2016 to 2018, Non-Executive Director at Immunocore Holdings Plc, and Executive Vice President at Evotec SE.
Dr. Howd started his career as a Research Analyst at ABN AMRO Bank NV (London Branch) in 2008 and later worked as a Research Analyst at Joh.
Berenberg, Gossler & Co. KG (United Kingdom) from 2009 to 2013.
He holds a doctorate degree from the University of London.